ArticleAntibody therapeutics2026

Development of SDP0505: a first-in-class HER3 × c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond.

Li-Min Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.